NRx Pharmaceuticals Presents Landmark Trial Of NRX-101 In Suicidal Bipolar Depression At The ASCP Annual Meeting: NRX-101 Is The First Oral Antidepressant Demonstrated To Reduce Suicidality In Bipolar Depression
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals presented its Phase 2b/3 trial results for NRX-101 at the ASCP Annual Meeting. The trial showed that NRX-101 significantly reduces suicidality and symptoms of akathisia in bipolar depression compared to the standard treatment, lurasidone.
May 28, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals presented positive Phase 2b/3 trial results for NRX-101, showing significant reductions in suicidality and akathisia in bipolar depression compared to lurasidone.
The positive trial results for NRX-101, demonstrating significant reductions in suicidality and akathisia, are likely to boost investor confidence and potentially increase the stock price of NRx Pharmaceuticals in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100